Experience with empagliflozin: insights from practice.
Session:
Improving cardiovascular outcomes in patients with type 2 diabetes: where does the evidence lead us?
Topic:
Diabetes, dysglycaemia and metabolic syndrome
Speaker:
Professor N. Marx (Aachen, DE)
Professor D. McGuire (Dallas, US)
Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)
Doctor J. Udell (Toronto, CA)
Sponsored by Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance
Event:
ESC Congress 2017
Congress Presentation
About the speakers
Professor Nikolaus Marx
RWTH University Hospital Aachen, Aachen (Germany)
46
presentations
10
followers
Professor Darren Keith McGuire
University of Texas Southwestern Medical Center, Dallas (United States of America)
20
presentations
0
follower
Professor Faiez Zannad
University of Lorraine, Vandoeuvre-Les-Nancy (France)
101
presentations
4
followers
Doctor Jacob Allan Udell
Women's College Hospital, Toronto (Canada)
9
presentations
0
follower
6 more presentations in this session
Introduction – Improving cardiovascular outcomes in patients with type 2 diabetes: where does the evidence lead us?
Speaker: Professor N. Marx (Aachen, DE)
Managing cardiovascular outcomes in patients with type 2 diabetes – Where have we come from and where are we going?
Speaker: Professor D. McGuire (Dallas, US)
Cardiovascular risk reduction with empagliflozin: exploring the evidence from EMPA-REG OUTCOME®.
Speaker: Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)
Using empagliflozin in your patients with type 2 diabetes:
considerations for daily patient care.
Speaker: Doctor J. Udell (Toronto, CA)
Access the full session
Improving cardiovascular outcomes in patients with type 2 diabetes: where does the evidence lead us?
Speakers:
Professor N. Marx, Professor D. McGuire, Professor F. Zannad, Doctor J. Udell, Professor N. Marx...
About the event
ESC 365 is supported by
